false advertising and illegal interstate marketing of CBD as an unapproved drug to treat diseases, such as cancer, osteoarthritis, symptoms of opioid withdrawal, Alzheimer's disease, and pet disorders. Chemical analysis of CBD products found that many did not contain the levels of CBD claimed in advertising. In 2022, the FDA stated that "scientific studies show possible harm to the male reproductive system, including testicular atrophy, harm to the liver, and interactions with certain medications. The FDA has not found adequate information showing how much CBD can be consumed, and for how long, before causing harm. This is particularly true for vulnerable populations like children and those who are pregnant." In December 2020, the Federal Trade Commission initiated a law enforcement crackdown on American companies marketing CBD products as unapproved drugs. The warning also applied to hemp CBD capsules and oil that were being marketed illegally while not adhering to the federal definition of a dietary supplement. See also Hash oil Hemp oil List of investigational antipsychotics List of investigational analgesics References Further reading External links 5-HT1A agonists Analgesics Anti-inflammatory agents Anticonvulsants Phytocannabinoids Cyclohexenes CYP2D6 inhibitors CYP3A4 inhibitors Endocannabinoid reuptake inhibitors Natural phenols 2,6-Dihydroxybiphenyls Orphan drugs